The APP ordered a bilateral diagnostic mammogram and left breast ultrasound that revealed extremely dense breast tissue, a ...

This episode’s guest, Melinda Mayorga, RN, MSN, CNS, AGCNS-BC, OCN, a clinical nurse specialist at Norris Comprehensive ...

The FDA has approved the use of subcutaneous amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for use in all approved ...

Young, Empowered, and Strong (YES), a mobile health intervention, was linked to improved general and cancer-specific ...

Hormone replacement therapy (HRT) does not have an adverse effect on breast cancer risk, according to findings from an ...

CAR T-cell therapy has revolutionized the treatment of certain hematologic malignancies, providing durable remissions for ...

The FDA has granted standard approval to rucaparib (Rubraca) for the treatment of patients with metastatic ...

Oncology nurses and APPs are key players in patient education on precision medicine.

The FDA has granted accelerated approval to subcutaneous treatment with mosunetuzumab (Lunsumio VELO™), a CD20xCD3 bispecific antibody, for adult patients with relapsed or refractory follicular ...

Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...

Experts discuss sequencing strategies in renal cell carcinoma (RCC), focusing on optimizing treatment selection after immune-oncology (IO)–based therapy.

The panel shares the most critical unmet needs for patients with endometrial cancer. Knowledge is power. Don’t miss the most recent breakthroughs in cancer care.